Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Diabetic Gastroparesis
NCT04254549Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in diabetic gastroparesis, sponsored by Mayo Clinic. Started Jun 2019; status: terminated.
02
Drugs
rifaximin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on NCT04254549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254549.